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Abstract: Prenatal nutrition is associated with offspring autism spectrum disorder (herein referred to
as autism), yet, it remains unknown if the association is causal. Triangulation may improve causal
inference by integrating the results of conventional multivariate regression with several alternative
approaches that have unrelated sources of bias. We systematically reviewed the literature on the
relationship between prenatal multivitamin supplements and offspring autism, and evidence for
the causal approaches applied. Six databases were searched up to 8 June 2020, by which time we
had screened 1309 titles/abstracts, and retained 12 articles. Quality assessment was guided using
Newcastle–Ottawa in individual studies, and the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) for the body of evidence. The effect estimates from multivariate
regression were meta-analysed in a random effects model and causal approaches were narratively
synthesised. The meta-analysis of prenatal multivitamin supplements involved 904,947 children
(8159 cases), and in the overall analysis showed no robust association with offspring autism; how-
ever, a reduced risk was observed in the subgroup of high-quality observational studies (RR 0.77,
95% CI (0.62, 0.96), I2 = 62.4%), early pregnancy (RR 0.76, 95% CI (0.58; 0.99), I2 = 79.8%) and prospec-
tive studies (RR 0.69, 95% CI (0.48, 1.00), I2 = 95.9%). The quality of evidence was very low, and
triangulation was of limited utility because alternative methods were used infrequently and often
not robustly applied.
Keywords: autism spectrum disorder; folic acid; maternal nutrition; meta-analysis; multivitamin;
systematic review
1. Introduction
Autism spectrum disorder (hereafter “autism”) is a neurodevelopmental condition
characterised by early-onset impairment in social communication and restricted and repet-
itive behaviour [1]. Prenatal nutrition may be a modifiable risk factor, which creates a
potential target for prevention strategies and may reduce the significant public health
implications of this condition. Autism in the U.K. is estimated to cost GBP 27 billion
(EUR 29.8 billion) annually for health, education, and social care and in lost productivity [2]
despite a modest prevalence of around 1.5% [3].
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Previous reviews and meta-analysis reported a reduced risk of offspring autism
associated with prenatal folic acid (FA) or multivitamin supplements [4,5], but as the
conventional rhetoric states: “correlation does not imply causation”. The conditions
necessary for estimating causality are greatly debated, and although randomised controlled
trials are considered to be the gold-standard, their utility in nutritional epidemiology is
limited because of ethical, financial, and practical barriers. For example, as the prevalence
of autism is only 1.5%, a large sample size is necessary for adequate statistical power,
but acquiring one is financially burdensome [6]. Conversely, a causal inference from non-
experimental studies is problematic, largely due to bias [7]. For example, individuals may
overreport compliance with prenatal nutritional supplements, creating a misclassification
bias, or confounders, which influence both the exposure and outcome, create a spurious
association.
Aetiological triangulation recognises that all approaches have bias and then exploits
unrelated sources of bias to “test” the consistency of results [7]. Causal inferences are
strengthened if we have consistent results across multiple approaches with different
sources of bias, as the biasmay vary across different study designs, methods or analytical
approaches. Some examples include conventional multivariate regression, gene-nutrient in-
teractions, discordant sibling studies, cross-context comparisons and negative controls (see
Lawlor et al. for an overview of approaches in triangulation [7]). We used the term “alter-
native causal approaches” to refer to the abovementioned approaches that are alternatives
to conventional multivariate regression.
Evidence from alternative causal approaches is unsystematically synthesised in pre-
vious reviews, if at all, which limits transparency. As alternative causal approaches are
increasingly applied within studies and may significantly alter causal reasoning, this evi-
dence should be integrated in an explicit and scientifically rigorous process. This aligns
with guidance from Cochrane [8] and a recent guideline on systematic aetiological reviews
of observational studies [9]. We first reviewed the overall evidence from studies using con-
ventional multivariate regression to investigate the association between prenatal nutritional
status and autism in offspring. Second, we narratively synthesised the causal approaches.
Lastly, we updated the search and addressed the limitations of previous reviews such as
double-counting individual studies [5,10], or using the DerSimonian and Laird estimator,
which can underestimate uncertainty [4,5].
2. Materials and Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
were followed [11] (Supplementary Table S1). The review protocol was registered on
the Prospective Register of Systematic Reviews, registration number: CRD42019154613.
Available online: https://www.crd.york.ac.uk/prospero (accessed on 23 July 2021).
2.1. Inclusion and Exclusion Criteria
The study designs were trials, cohort, case-controls and cross-sectional studies of any
duration. We focused on the use of folic acid and multivitamin supplements (hereafter
simply “multivitamin supplement”) in women during preconception and prenatal periods
because folic acid is generally sourced from a multivitamin supplement [4]. Compara-
tors were high versus low or no supplement intake. The outcome was offspring autism
diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, Interna-
tional Classification of Disease, and health registers. There were no date limitations, but
non-English language and animal studies were excluded.
2.2. Study Identification and Selection
The search strategy and selection of databases were guided by an information scientist
with expertise in systematic reviews. Search strategies were adapted to each database.
The following databases were searched from the earliest date to 8 June 2020; MEDLINE
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(OVID), EMBASE (OVID), PsycINFO (EBSCO), Web of Science core collection, Open Grey
and BioRix. See Table 1 for MEDLINE search strategy.
Table 1. Search strategy for MEDLINE (OVID).
Search String Search Terms
Population (Pregnancy OR Fetal development OR Prenatal).af. OR Fetal development/OR“fetal development”.af. OR “fetal programming”.af OR “fetal programing”.af
Exposure
NUTRITIONAL PHYSIOLOGICAL PHENOMENA OR Prenatal Nutritional
Physiological Phenomena/OR Maternal nutritional physiological
phenomena/OR DIET OR nutri* OR vitamin OR diet* OR mineral OR
Nutritional Status
An asterisk (*) is used as truncation in Medline and allows any word ending.
Titles and abstracts were screened, full articles reviewed, and quality assessment
was completed twice independently for each study, by C.F., T.B., and M.S. Disagreements
were resolved through discussion and adjudicated, by J.A. Data were extracted by C.F.
using a standardised form comprised of, author, year of publication, country and cohort,
study design, sample size, age of participants, nutritional supplement, measure of autism,
covariates, results, and causal approach.
2.3. Quality Assessment
The Newcastle–Ottawa Scale guided the quality assessment of each observational
study. Scores range from 0 to 9, where a score of 7–9 was considered high quality in the
subgroup analysis and consistent with similar previous reviews [5,12]. The Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach was
used to rate the body of evidence based on the degree of certainty in the result [8].
2.4. Data Synthesis and Analysis
We narratively synthesised studies that were inappropriate to meta-analysis. Addi-
tionally, we summarised the alternative approaches applied in table format.
2.5. Meta-Analysis
We conducted a meta-analysis of the fully adjusted effect estimates in a random effects
model using the Hartung–Knapp–Sidik–Jonkman estimator [8]. Analyses of nutritional
supplements were pooled if the exposure was categorical: no or low supplement intake
as the reference category compared against supplement use. Autism is a rare outcome,
so we assumed the odds ratio (OR) and hazard ratio (HR) were directly comparable to
the relative risk (RR) [13]. The heterogeneity was measured with the Cochrane’s q and
I2 statistics. The interpretation of heterogeneity (I2) was guided by Cochrane’s reference
ranges [8]. Prediction intervals estimated the range of effect estimates that may be expected
in individual settings that could improve the application of the research findings. These
are distinct from the summary effect and 95% confidence intervals (CIs) that estimate the
average effect of the exposure [8,14,15]. The R version 3.6.3 packages used were “meta”
and “forestplots” [16]. Statistical tests of significance were 2-sided with an α of 0.05.
2.6. Sensitivity Analysis
Sources of heterogeneity were explored through the identification of outliers, leave-
one-out analysis and subgroup analysis if there were ≥10 studies. A random effects model
was used to estimate between and within subgroup effects. The pre-defined subgroups
were study quality, study design (prospective/retrospective), region, mandatory fortifica-
tion (yes/no), and stage of pregnancy, which was defined as the first trimester, compared
against any point in pregnancy, if the nutritional supplement exposure period was unde-
fined. Between-subgroup differences were measured with the q statistic and significance
was indicated by p < 0.1 (2-sided). Small-study publication bias was assessed through the
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inspection of the funnel plot and Egger’s test [17]. The widely used DerSimonian and Laird
estimator may underestimate uncertainty [8], but to facilitate comparison with previous
research, we applied it in sensitivity analyses.
3. Results
3.1. Identification of Studies
A total of 1309 titles were identified with 342 duplicates, leaving 967 titles and abstracts
to be screened (Figure 1). Of these, 897 were excluded based on title and abstract review,
leaving 70 for a full-text review, of which 13 met the inclusion criteria. However, two
reports were duplicated [18,19], and so the larger cohort was retained [19] leaving 12
studies in the final review, 10 of which were meta-analysed. The other two were narratively
synthesised because the reference category was not low or no supplement use [20,21].
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10 meta-analysed
Figure 1. PRISMA flow chart of study selection.
3.2. Quality Assessment
Based on the Newcastle–Ottawa Scale, five [20,22–25] of seven cohort studies
[19,20,22–26] were of high quality, and two [27,28] of five case-control studies [21,27–30]
were of high quality (Supplementary Tables S2 and S3). The quality of the body of evidence
based on GRADE was very low (Table 2). The details for the evidence profile and rationale
for GRADE rating are provided in Supplementary Tables S4 and S5. For a summary of
studies and results, see Table 3.
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3.3. Meta-Analylic Results
A total of 904,947 children including 8159 cases from six countries were included in
the meta-analysis. All studies measured nutritional supplements and one included fortified
food. The multivitamin dose was seldom reported.
Overall, there was no robust evidence to associate taking prenatal multivitamins with
autism risk compared to no/low intakes (RR 0.74, 95% CI: 0.53, 1.04) (Figure 2). The
confidence intervals (CI) were wide, and there was considerable heterogeneity (I2 = 94.3%,
p < 0.001). Egger’s test (p = 0.44) and inspection of the funnel plot suggests no evidence of
asymmetry (Supplementary Figure S1). The precision increased when the DerSimonian and
Laird estimator was applied compared to the Hartung–Knapp–Sidik–Jonkman estimator
(RR 0.74, 95% CI: 0.57, 0.95, I2 = 94.3%). Upon removal of the outlier, DeSoto and Hitlan,
there was a 32% reduced risk of autism (RR 0.68, 95% CI: 0.51, 0.91, I2 = 94.7%, p < 0.001);
although heterogeneity remained considerable. There were no other influential studies
(Supplementary Table S7). The 95% prediction interval indicated that the dispersion in the
distribution of effect estimates was large and ranged from a reduced to an increased risk of
autism (RR 0.21, 2.59).
Subgroup Analysis
See Supplementary Figures S2–S6. In high-quality observational studies there was a
23% reduced risk of autism associated with maternal multivitamin use, and heterogeneity
was reduced from considerable to substantial (RR 0.77, 95% CI: 0.62, 0.96, I2 = 62.4%). No as-
sociation was observed in low-quality studies (RR 0.78, 95% CI: 0.33, 1.86, I2 = 97.9%), and
there were no between-subgroup differences detected Q = 0.00, p = 0.98). Some evidence of
association was observed in prospective studies (RR 0.69, 95% CI: 0.48, 1.00, I2 = 95.9%),
whilst no association was evident in the retrospective studies (RR 0.93, 95% CI: 0.41, 2.11,
I2 = 81.7%). There were no differences between subgroups for study design (Q = 0.42,
p = 0.51). Subgroup analysis of regions reduced heterogeneity from “considerable” in
Nordic (RR 0.87, 95% CI: 0.72, 1.06, I2 = 76.8%) and American (RR 0.87, 95% CI: 0.5, 2.15,
I2 = 84.5 %) studies. Asian countries had the largest effect estimate, but there was con-
siderable heterogeneity (RR 0.56, 95% CI: 0.26, 1.23, I2 = 97.1%). No differences between
subgroups were detected (Q = 1.14, p = 0.57). Subgroup analysis of the stage of pregnancy
showed similar effect estimates in each group (early pregnancy: RR 0.76, 95% CI: 0.58, 0.99,
I2 = 79.8%; any stage of pregnancy: RR 0.78, 95% CI: 0.40, 1.53, I2 = 96.6%). There were no
between-subgroup differences (Q = 0.01, p = 0.93). Regions without mandatory fortification
produced a stronger reduction in the risk of autism (RR 0.71, CI 95%: 0.50, 1.02, I2 = 96%),
compared to regions with mandatory fortification (RR 0.87, CI 95%: 0.35, 2.15, I2 = 84%).
There were no between-subgroup differences detected (Q = 1.14, p = 0.57).
Table 2. Summary of GRADE evaluation.
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Table 3. Study characteristics and results from individual studies [19–30].
Author/Study Design Country/Cohort/Sample Exposure Measure (S) OutcomeMeasure Covariates
a Results
Effect Size Estimate and 95% CI
Desoto and Hitlan, 2012
[29]/case-control
USA
256 cases and 752
controls,
age range 6–12 years
Self-reported FA or
multivitamin supplement
use obtained from health
records
ICD-9
Child; anaemia, pica, sex, birth weight, birth order, year of birth, breast
feeding, sex and FA interaction
Maternal; age, poverty ratio, adequacy of prenatal care, cholesterol screen,
pap smear, prenatal alcohol use, prenatal viral infections, lead exposure
Reference, no supplement use
FA/multivitamin
HR 2.34 1.14, 4.82
DeVilbiss et al., 2017
[22]/population-based





age range 4–15 years
Self-reported multivitamin
supplement use recorded by
midwife at first booking
DSM-IV or
ICD-10
Child; sex, birth year, and years of residence in Stockholm County
Maternal; country of birth, maternal education, disposable family income,
age, parity, smoking, BMI at first antenatal visit, neurologic or psychiatric
conditions before the child’s birth (anxiety disorders, autism, bipolar
disorder, depression, intellectual disability, non-affective psychosis, stress
related disorders, epilepsy), antiepileptics and antidepressants medication
Sibling analysis
child sex and birth year, maternal parity
Reference, no supplement use
Multivitamin
OR 0.89 0.82, 0.97
Sibling analysis, multivitamin
OR 0.95 0.81, 1.13
Propensity score matching
OR 0.86 0.78, 0.95






572 cases and 45,300
controls average age





Child; sex, birth year
Maternal; parity, socioeconomic status (high vs low), psychiatric diagnosis
by childbirth, age
Paternal psychiatric diagnosis, age
Reference, no supplement use
FA/multivitamins
RR 0.27 0.22, 0.33
Negative control
Reference, no supplement use
Multivitamin use 2 years prior to
pregnancy
0.12 0.07, 0.20





354 cases and 374
controls,
average age 4.5 years
Self-reported FA
supplements DSM-IV-TR
Child; age, premature birth, gender
Maternal; pre-pregnancy BMI preconception and predelivery, mode of
delivery
Parental; age, education
Dietary patterns were additionally adjusted for other dietary patterns
FA and calcium supplements: were additionally adjusted for other
supplements.
Reference, no supplement use
FA
OR 0.64 0.41, 1.00





2009 cases and 19,886
controls





Child: sex, birth year, birth order
Maternal: age, region of residence, poverty index, number of physician
visits, diabetes mellitus, hypertension, cardiovascular disease, cancer,
subfertility, epilepsy, antifolate medication (proguanil, methotrexate,
sulfasalazine, sulphamethoxazole and trimethoprim, pyrimethamine,
valproate, carbamazepine, phenytoin and phenobarbital)
Final model adjusted for; maternal age, subfertility, number of physician




OR 1.15 0.98, 1.24
0.4–<1 mg/day
OR 1.10 0.98, 1.24
1 < 3 mg/day
OR 1.14 0.98, 1.34
≥3 mg/day
OR 1.01 0.60, 1.70
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Table 3. Cont.
Author/Study Design Country/Cohort/Sample Exposure Measure (S) OutcomeMeasure Covariates
a Results
Effect Size Estimate and 95% CI










Child; sex, gestational age birth year
Maternal; homocysteine, race, age, smoking status, diabetes, reduction,
parity, MTHFR 677 genotype, BMI
Reference, multivitamins 2–5
times/week
First trimester ≤ 2/week
HR 3.4 1.6, 7.2
>5/week
HR 2.3 1.2, 3.9
Second trimester ≤ 2/week
HR 3.8 1.8, 8.0
>5/week
HR 2.1 1.2, 3.6
Third trimester
≤2/week
HR 3.5 1.7, 7.4
>5/week
HR 2.1 1.2, 3.6
Schmidt et al., 2019
[23]/prospective cohort
USA/Markers of















Child; birthplace, sex, year of birth
Maternal; education, age, pre-pregnancy BMI, planned pregnancy,
race/ethnicity, home ownership, insurance delivery type.
Paternal; age
Covariates in final model, maternal characteristics (education, age,
insurance delivery type) and child characteristics (race)
Reference, no supplement use
Multivitamin
RR 0.50







429 cases and 278
controls




















Child; birth year, sex, race
Maternal; race, age, education, pre-pregnancy BMI, birthplace, residing with
a smoker, smoking status, alcohol consumption, other nutrients intakes
(calcium, iron, vitamin A, B6, B12, C, D and E)
Preeclampsia, type of delivery, vaginal bleeding during pregnancy, induced
labour
Paternal: age
Covariates in final model; childbirth year and maternal education
Reference, no supplement use
All strata combined
OR 0.62 0.42, 0.92
Strata by C/T genotypes
maternal CC
OR 1.20 0.61, 2.34
maternal CT/TT
OR 0.46 0.25, 0.85
child CC
OR 1.15 0.55, 2.38
child CT/TT
OR 0.48 0.27, 0.88
both mother & child
OR 1.29 0.54, 3.10
either mother or child CT/TT
OR 0.49 0.16, 1.50
both mother and child CT/TT
OR 0.30 0.10, 0.90
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Table 3. Cont.
Author/Study Design Country/Cohort/Sample Exposure Measure (S) OutcomeMeasure Covariates
a Results
Effect Size Estimate and 95% CI
Suren et al., 2013
[24]/prospective cohort
Norway/Norwegian
mother, father and child
cohort (MoBa)
85,176/114 cases,








Maternal; planned pregnancy, smoking, BMI, parity, weight gain at 18 and
30 weeks
Parental; education, age
Covariates retained in final model; birth year, parity and maternal education
Reference, no supplement use
FA/multivitamins
OR 0.61 0.41, 0.90
Negative control
Reference, no fish oils supplements
Fish oil supplements
OR 1.29 0.88, 1.89












Maternal; age, parity, smoking, education, socioeconomic status (based on
occupation and education), planned pregnancy, pre-pregnancy BMI
Paternal; age
Reference, no supplement use
FA/multivitamins
HR 1.06 0.94, 1.19
Tan et al., 2020
[21]/case- control
China
416 cases and 201
control





Child; age, sex, gestational age, birth weight




















Maternal; age, marital status, parity, hospital size
Paternal; age
Reference, no supplement use
FA
OR 0.86 0.78, 0.95
a All covariates initially considered relevant by the authors are listed as well as the final selection. Initialisms: BMI, Body Mass Index; DSM, Diagnostic and Statistical Manual of Mental Disorders; DSM-IV-TR,
Diagnostic and Statistical Manual of Mental Disorders Text Revision; FA, folic acid; GDM, gestational diabetes mellitus; GWG, gestational weight gain; ICD, International Classification of Disease; SD standard
deviation; MTHFR 677, Methlyenetetrahydrofolate reductase 677 (genotype); CT/TT/CC, genotype variants; Q, Quintle; SNP, single-nucleotide polymorphism.
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3.4. Causal Approaches
All studies [19,22–30] measured the association between prenatal nutrition and autism
using conventional multivariate regression. Alternative causal approaches (one discordant
sibling analysis, two negative controls studies, and one genetic interaction study) were
infrequently applied (Table 4) and were generally used as a secondary analysis to con-
ventional multivariate regression. A detailed summary of the key sources of bias in each
approach can be read in Supplementary Table S6.
Table 4. Summary of causal approaches which demonstrates multivariate regression was commonly applied whilst all other
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Effect direction: N indicates a positive health impact, H indicates a negative health impact. Significance association indicated with a black
arrow, no association is indicated with an unshaded arrow (∆, ∇); The nutrient source is supplements/fortified food (reference group:
no/low intake); a Raghavan et al. reference group is 3–5/week compared to low and high supplements intakes; b negative control was two
years pre-pregnancy and had a stronger association with autism; c Beneficial effects of folic acid supplements were only detected if the
child or mother had at least one T allele which reduces the efficiency of folate metabolism; d negative control was fish oils, which showed
no association with autism.
4. Discussion
Prenatal multivitamin supplements were not robustly associated with autism in the
overall meta-analysis. However, a reduced risk of autism was observed in high-quality stud-
ies, prospective studies, early pregnancy and following the removal of an outlier. In contrast
with previous meta-analyses, we did not observe any strong evidence of association in our
main results (using all studies) due to the selection of the Hartung–Knapp–Sidik–Jonkman
estimator, rather than DerSimonian–Laird which underestimates uncertainty and was ap-
plied in previous meta-analysis [4,5,31]. We also identified an additional two studies [21,27].
However, although some associations were identified, based on GRADE the degree of
certainty was very low owing to the inherent risk of bias in observational study designs,
considerable heterogeneity, and unexplained inconsistency in the direction of effect. As
GRADE does not easily incorporate alternative causal approaches [32], we structured the
discussion first to discuss the limitations identified through the application of GRADE.
Second, we evaluated whether the alternative causal methods had been of value to the
interpretation of causality.
Regional variation in baseline nutritional status and genotype [5,33] may be major
contributors to both heterogeneity and inconsistency in the direction of the effect. Nutrients
confer a benefit to health until physiological requirements are satisfied; thereafter, we
observe a plateau effect, and toxicity or deficiency occurs when intakes are extreme [34].
To illustrate this potential U-shaped relationship, we considered baseline folate status.
Studies in this review from Nordic countries generally showed effect estimates closest to
the null, except Norway [24,25]. The Nordic associations correlated with rates of plasma
folate deficiency/insufficiency, which were reported to be 0.7% in Denmark [35], 4%
in Sweden [36], but 24.9% in a subsample of the Norwegian mother, father and child
cohort [37]. However, the comparisons between supplement use and plasma folate levels
were drawn from different populations, and population heterogeneity and confounding
may have caused variance at the individual level. Future studies should consider the
response to nutritional supplements in relation to baseline nutritional status.
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Furthermore, from the reviewed studies, only the U.S. implements mandatory fortifi-
cation of diet with folic acid and so has a high baseline folic acid intake. Less than 1% of
its population has had deficient plasma folate levels since the introduction of mandatory
fortification in 1998 [38], but this may have reduced the benefits from supplements since
physiological requirements are already met. However, a plateau effect was not observed.
Instead, two U.S. studies found a reduced risk of autism associated with multivitamin
supplements [23,28], and two studies observed an increased risk of autism [20,29]. There
is much uncertainty and debate as to whether toxicity could occur through the combined
effects of mandatory fortification and supplementation with folic acid. [39]. Wiens and
DeSoto (2017) argued that excessive intake saturates metabolic pathways, leading to an
accumulation of unmetabolized folic acid which may cause autism [39]. Furthermore,
folic acid is absorbed more readily than the folate form and is used in supplements and
fortified food which the authors argued further exacerbates excessive intake. However,
other research groups found inconclusive evidence to support such claims, even though
limitations in available evidence were acknowledged [40].
The two studies in this review that observed a reduced risk of autism had folic acid
intakes well in excess of the recommended 400 ug/day [23,28], yet they focused on early
pregnancy when, it is speculated, folic acid requirements and tolerance to high doses is
greater. An alternative explanation for the increased risk of autism is “birth order bias” [41].
Autism and supplement use can be positively correlated independently, as supplement
use is usually greater in first pregnancies, and families affected by autism have fewer
children. Indeed, an increased risk of autism in Moser et al. was attenuated to the null with
restrictions to first-born boys [27].
An additional source of heterogeneity is variation in the stage of pregnancy when the
multivitamin supplement was taken. In early pregnancy it was associated with a lower
risk of autism and lower heterogeneity. Periconception is an established critical period in
which FA can reduce the incidence of neural tube defects by up to 70% [42]. Furthermore,
FA in periconception may reduce the risk of low birth weight, small gestational age size,
stillbirth, neonatal mortality, preeclampsia and miscarriage [42].
Lastly, autism is a heterogeneous condition and specific features might have dif-
ferential causal pathways [43], which may contribute to varied results. All studies that
stratified by severity, observed a greater magnitude of association with more severe forms
of autism [21,22,24,26] as defined by minimal verbal status at age 3 [24], low intelligence
quotient [22,26], or high autism symptom severity [21].
4.1. Alternative Causal Approaches
4.1.1. Multivariate Regression
Alternative causal approaches were infrequently applied, and the application was
often not robust; therefore, our ability to triangulate the findings was limited. All studies
used multivariate regression, a key assumption of which is no residual confounding [7].
However, there was such a risk in this review as studies were adjusted for many, but
seldom all, key confounders. The studies commonly adjusted formaternal age, physical or
mental health, socioeconomic status, parity, planned pregnancy, pre-pregnancy BMI, and
health behaviour. Due to the risk of residual confounding we attempted to triangulate the
results from the multivariate regression with alternative approaches that have different
sources of bias. However, only the gene-nutrient interaction analysis provided useful
results.
4.1.2. Gene-Nutrient Interaction
In Schmidt et al., an association between folate use and autism risk was only observed
if the mother/child had the methylenetetrahydrofolate reductase (MTHFR) 677 C > T
genotype, which is unlikely owing to confounding by socioeconomic and lifestyle char-
acteristics [28]. The MTHFR 677 C > T genotype encodes for a less-efficient enzyme to
metabolise folate. Hence, larger folate doses may be necessary to overcome inefficient enzy-
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matic function [28]. Although these findings are yet to be replicated in larger samples, there
is consistency in the wider literature. A recent meta-analysis identified an 86% increased
risk of autism associated with the less-efficient genotype (TT genotype verses CC genotype:
OR 1.86, 95% CI: 1.12, 2.18) [44]. Furthermore, this association was not evident in countries
that had a higher intake of folic acid secondary to mandatory folic acid fortification. This
may imply that a genotype influences the response to supplements or mandatory folic acid
fortification.
4.1.3. Discordant Sibling Analysis
Discordant sibling analyses may overcome shared unmeasured confounding despite
several key methodological considerations. In DeVilbiss et al., the reduced risk of autism
observed in their main analysis was attenuated by the discordant sibling analysis [22].
Sibling comparison studies are a quasi-experimental study design intended to remove
shared familial confounding by matching siblings discordant for the outcome. However,
this includes shared genetic risk factors [7], and siblings share, on average, 50% of their
genetic material. As indicated in Schmidt et al.’s study, it may be the combination of
MTHFR 677 C > T genotype and no folic acid supplements that led to an increased risk
of autism. Thus, this sibling comparison may have adjusted for a causal component.
Furthermore, there is a high type II error rate as only siblings discordant for the exposure
and outcome contribute to the effect estimate in conditional logistic regression models [45].
DeVilbiss et al.’s discordant sibling analysis may be underpowered because the confidence
intervals were wider even though the point estimate was consistent with the main analysis.
Furthermore, random error can be amplified in discordant sibling analysis and bias towards
the null. Conversely, time-varying confounders should be adjusted as matching on siblings
does not account for this [45]. Thus, the null association observed here should be interpreted
with caution as it could reflect a type II error or adjustment for a causal component, MTHFR
genotype.
4.1.4. Negative Control
In two studies, negative controls were applied and acted as mock exposures that
indicate the presence of bias without relying on the assumption of no unmeasured con-
founding [46]. Instead, they depend on the assumption that confounding, and sometimes
other biases, were similar in exposure and negative control analyses. A further assumption
was that the negative control had no plausible relationship with the outcome. Therefore,
the exposure–outcome relationship could be distinguished from bias by comparing the
strength of the association with the negative control analysis [7], but the assumptions
were empirically untestable. Thus, we were limited to a subjective interpretation based on
subject knowledge [46] which is presented here.
Suren et al. measured an association with multivitamin supplements, but not fish
oils [24] even though they are a rich source of polyunsaturated fatty acids, especially
omega-3s, and cod liver oil is a rich source of vitamin D, both of which are associated
with positive neurodevelopmental outcomes [47,48]. Conversely, cod liver oil is a rich
source of vitamin A which is potentially teratogenic and can harm foetal development [49].
Thus, this negative control violates the assumption of no plausible relationship with the
outcome, which confused the interpretation. Similarly, Levine et al.’s negative control may
have had a relationship with the exposure. The authors compared mutually exclusive
groups for multivitamins: two years prior to pregnancy, two years prior to pregnancy and
during pregnancy, and during pregnancy only. All groups were associated with a reduced
risk of autism, yet the association was strongest and most similar for “two years prior to
pregnancy” and “two years prior to pregnancy and during pregnancy”. No “wash-out”
period was used, so two years prior to pregnancy may have included the potentially
critical period, preconception. Furthermore, the assumption of similar bias may not be met
either since women who discontinue supplements during pregnancy may have different
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characteristics to women who adhere to health advise and take the supplements during
pregnancy. Thus, we lacked confidence in this negative control.
4.1.5. Triangulation
Collectively, triangulation as a strategy to further causal interpretation was limited,
many due to infrequent use and limitations in applying alternative approaches. The
multivariate regression and gene-nutrient interaction [24] findings suggest there could
have been a causal association, and we feel this warrants further investigation. However,
within the context of this review, the discordant sibling analysis [22] and negative control
analyses [24,26] were of limited utility. The former needs to be conducted on larger samples
and adjusted for a range of time-varying confounders, and the choice of the latter should
be given careful consideration.
4.2. Strengths and Limitations
This review has several strengths. Numerous steps to reduce bias were taken, such
as searching grey literature sources, applying GRADE guidelines, calculating prediction
intervals and using the Hartung–Knapp–Sidik–Jonkman estimator. However, the strongest
advance was a formal narrative synthesis of the range of causal approaches. As an explicit
approach, it provided transparent evidence of the approaches applied, their findings
and outlined areas for future studies. Nonetheless, there were weaknesses, mainly the
heterogeneity and inconsistency observed across studies and the low study numbers.
The prediction intervals indicated if there had been an effect, it could have ranged from
beneficial to null or even harmful in individual settings.
5. Conclusions
At present, the evidence is inconclusive, and we are unable to confirm a causal
association between prenatal multivitamin supplement use and autism in offspring. Future
studies should improve the study design and data analyses through adequately powered
prospective birth cohorts. The measurement of nutritional supplements could be improved
through reporting their nutrient composition, dose, compliance and duration and timing
of use, which are all known to affect biological responses but were rarely considered
in the studies we reviewed. Furthermore, there should be greater consideration of the
complexity of nutrition by modelling U-shaped relationships and considering how the
response to nutrients is altered by variations in baseline requirements and whether it is
affected by recent nutrient intake, changes to physiological demand in early pregnancy, or
genetic variation. Lastly, we recommend the application of alternative approaches within a
triangulation framework to gauge causality better.
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